WVE Stock Forecast & Price Target

Wave Life Sciences is fundamentally attractive because its PRISM platform supports multiple RNA modalities, giving the company a differentiated engine for potentially best-in-class medicines across rare and prevalent diseases. The clearer FDA-aligned path for WVE-006, including a single two-year registrational trial with a one-year interim analysis and no separate confirmatory study, improves development efficiency while the ongoing WVE-007 obesity program broadens upside through monotherapy, combination, and maintenance settings. With four clinical programs advancing, a $12M GSK milestone, about $431.0M in cash and investments at 3Q, and runway into 3Q28, the company has both strategic optionality and financial durability to support its pipeline.

Wave Life Sciences is viewed negatively because WVE-006’s ATS 2026 data, while validating RNA editing, showed total AAT of 13.6 µM at 400 mg and 11.9 µM at 200 mg, both below BEAM-302’s 16.1 µM and Sanofi’s 24.1 µM, raising doubts about commercial competitiveness. The readout also suggested a saturating dose-response, with 600 mg single-dose AAT falling to 13.0 µM and M-AAT% capped around 64%, implying a mechanistic ceiling rather than a simple dosing issue. Regulatory and competitive risks remain elevated because BEAM-302 has a 12–18 month lead with a pivotal cohort initiating 2H 2026, while Wave’s composite biomarker strategy is still unvalidated and depends on mid-2026 FDA feedback.